Trial Profile
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Romidepsin (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 30 Apr 2021 Planned primary completion date changed from 1 Jul 2022 to 1 Dec 2021.
- 30 Apr 2021 Status changed from recruiting to active, no longer recruiting.